Artelo comments on White House Executive Order expanding CBD research

Artelo Biosciences (ARTL) commented on the White House’s recent Executive Order establishing a Medicare pilot program to support reimbursement and structured data collection for cannabidiol, CBD, products. Artelo views the Administration’s action as a “significant milestone” in the recognition of CBD’s therapeutic potential. The Company believes the federal government’s “emphasis on data collection to inform future research and potential expansion to Medicaid and broader patient populations highlights a growing demand for safe, effective, and well-characterized CBD therapies,” the company said.